Platelets properties study in patients with different stages of schizophrenia

The aim of study: to compare platelet properties — their number, degree of activation in patients with different severity of schizophrenia: risk of schizophrenia (high and ultra-high risk), in patients with 1-st attack of schizophrenia and chronic patients with schizophrenia Materials and methods: we used several psychometric scales — SOPS scale to assess the risk of schizophrenia, PANSS scale — to assess the severity of psychotic symptoms in patients with schizophrenia. Activation of the platelets during gel fltration was estimated from the difference in the number of cells at the inlet and outlet of the column. Results: the results showed a consecutive reduction of the platelets number in platelet-rich plasma (PRP) obtained by centrifugation, in patients with increasing severity of schizophrenia — patients with risk of schizophrenia (high and ultra-high risk), 1-st attack of schizophrenia, chronic schizophrenic patients. The number of platelets after centrifugation in patients with high risk of schizophrenia is 1,56 times (p < 0,009) exceeds this value in patients with the 1-st attack of schizophrenia and 4,30 (p < 0,000001) times exceeds in chronic patients with schizophrenia. It was also shown the signifcant differences in the properties of platelets in patients with 1-st attack versus chronic patients with schizophrenia: the number of platelets after centrifugation in patients with 1-st attack of schizophrenia is 2,75 times (p < 0,0001) higher than the number of cells in chronic schizophrenic patients. The number of platelets from chronic schizophrenic patients is 1,8 times (p < 0,001) less than the number of platelets from healthy donors. The number of cells in patients with 1-st attack of the disease does not differ from corresponding values in healthy donors. Gel fltration in patients at the height of mental disorders revealed the platelet activation in all groups of examined patients. Conclusion: it was assumed that the higher values of number of platelets in patients with risk of schizophrenia make for the more positive output of the attack without mental deterioration, and a less signifcant number of platelets after centrifugation in patients with schizophrenia was the factor leading to the deterioration of the patient.

1. Davidson L., Schmutte T., Dinzeo T., Andres-Hyman R. Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr. Bull. 2008;34(1):5–8.

2. Harvey C.A., Jeffreys S.E., McNaught A.S., Bizard R.A., King M.B. The Camden Schizophrenia Surveys III: Five-year outcome of a sample of individuals from a prevalence survey and the importance of social relationships. Int. J. Soc. Psychiatry. 2007;53 (4):340–356.

3. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996;22(2):353–370. PMID:8782291

4. Kaleda V.G., Mezenceva O.E., Krylova E.S., Barhatova A.N. Osobennosti domanifestnogo ehtapa ehndogennogo psihoza s pervym pristupom v yunosheskom vozraste. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112(5):22–28. (In Russ.).

5. Omel'chenko M.A., Golubev S.A., Nikiforova I.Yu., Kaleda V.G. Risk manifestacii ehndogennyh psihozov u bol'nyh s nepsihoticheskimi psihicheskimi rasstrojstvami yunosheskogo vozrasta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014; 114(6):14–20. (In Russ.).

6. Klyushnik T.P., Omel'chenko M.A., Sarmanova Z.V., Zozulya S.A., Otman I. N., Dupin A. M. Vozmozhnost' ispol'zovaniya immunologicheskih pokazatelej dlya ocenki riska razvitiya ehndogennyh psihozov u bol'nyh s nepsihoticheskimi rasstrojstvami yunosheskogo vozrasta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;114(10):97–101. (In Russ.).

7. Habets K.L., Huizinga T.W., Toes R.E. Platelets and autoimmunity. Eur. J. Clin. Invest. 2013;43(7):746–757. doi:10.1111/eci.12101

8. Klinger M.H., Jelkmann W. Role of blood platelets in infection and inflammation. J. Interferon. Cytokine Res. 2002;22(9):913–922.

9. Sherbakova I.V., Kaleda V.G., Barhatova A.N., Klyushnik T.P. Markery ehndotelial'noj disfunkcii pri pristupoobrazno-progredientnoj shizofrenii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2005;105(3):43–46. (In Russ.).

10. Belsham B. Glutamate and its role in psychiatric illness. Hum. Psychopharmacol. 2001;16(2):139–146. doi:10.1002/hup.279

11. Zlobina G.P., Brusov O.S., Morozova M.A., Beniashvili A.G. Osobennosti vydeleniya i sostoyanie trombocitov u bol'nyh shizofreniej. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova . 2009; 109(10):47–50. (In Russ.).

12. Brusov O.S., Zlobina G.P. Osobennosti izmeneniya aktivacii trombocitov u bol'nyh hronicheskoj shizofreniej v zavisimosti ot stepeni tyazhesti pozitivnyh i negativnyh simptomov pri formirovanii remissii. Vestnik RAMN. 2013;9:42–45. (In Russ.).

13. Tangen O., Berman H. J., Marfey P. Gel Filtration. A new technique for separation of blood platelets from plasma. Thromb Diath. Haemorrh. 1971;25(2):268–278.

14. Kaleda V.G. Pervyj psihoticheskij ehpizod yunosheskogo ehndogennogo psihoza i ego tipologicheskie raznovidnosti. Psihiatriya. 2006;22–24(4–6):7–15. (In Russ.).

15. McGlashon T., Miller T., Woods S., Hoffman R., Davidson L. A scale for the assessment of prodromal symptoms and state. In: T. Miller, S. Mednick, T.M. Glashon, G. Liberger, J. Johannnessen. The Neth- erlands: Kluwer Academic Publishers, 2001;135–149.

16. Kay S.R., Fiszbein A., Lindenmayer J.P., Opler L.A. Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr. Scand. 1986;74(5):507–518.

17. Zarbock A., Polanowska-Grabowska R.K., Ley K. Platelet-neutrophilinteractions: linking hemostasis and inflammation. Blood Rev. 2007;2(3):99–111.